S100 and Impact of ECT on Depression and Cognition

Arts, Baer; Peters, Maarten; Ponds, Rudolf; Honig, Adriaan; Menheere, P. P. C. A.; Os, Jim van

doi:10.1097/01.yct.0000235925.37494.2c

Cited by 30 publications

(20 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This meta-analysis identified three studies involving 46 patients with major depression and one study including 11 patients with mania. A fifth study examining changes in serum S100B immediately (1 and 3 hours) after electroconvulsive treatment did not include a control group [80] and because injury mechanisms following electroconvulsive treatment could represent a potential confounding factor, we did not include this study in the meta-analysis. A sixth study [56] did not differentiate between therapy-resistant major depression and schizodepressive psychosis when reporting their findings during electroconvulsive therapy, and was, accordingly, also excluded.…”

Section: Treatment Effects On Serum S100bmentioning

confidence: 99%

Mood Disorders Are Glial Disorders: Evidence from In Vivo Studies

Schroeter

Abdul‐Khaliq

Sacher

et al. 2010

Cardiovascular Psychiatry and Neurology

View full text Add to dashboard Cite

It has recently been suggested that mood disorders can be characterized by glial pathology as indicated by histopathological postmortem findings. Here, we review studies investigating the glial marker S100B in serum of patients with mood disorders. This protein might act as a growth and differentiation factor. It is located in, and may actively be released by, astro- and oligodendrocytes. Studies consistently show that S100B is elevated in mood disorders; more strongly in major depressive than bipolar disorder. Successful antidepressive treatment reduces S100B in major depression whereas there is no evidence of treatment effects in mania. In contrast to the glial marker S100B, the neuronal marker protein neuron-specific enolase is unaltered. By indicating glial alterations without neuronal changes, serum S100B studies confirm specific glial pathology in mood disorders in vivo. S100B can be regarded as a potential diagnostic biomarker for mood disorders and as a biomarker for successful antidepressive treatment.

show abstract

Section: Treatment Effects On Serum S100bmentioning

confidence: 99%

Mood Disorders Are Glial Disorders: Evidence from In Vivo Studies

Schroeter

Abdul‐Khaliq

Sacher

et al. 2010

Cardiovascular Psychiatry and Neurology

View full text Add to dashboard Cite

show abstract

“…This activation is suggested to be a main contributor for the antidepressant effect of ECT [ 42 , 43 ]. Solely, one clinical study measured a small but significant elevation of S100B one hour after ECT administration associated with poorer memory function [ 44 ].…”

Section: Introductionmentioning

confidence: 99%

S100B, Homocysteine, Vitamin B12, Folic Acid, and Procalcitonin Serum Levels in Remitters to Electroconvulsive Therapy: A Pilot Study

et al. 2018

View full text Add to dashboard Cite

Background Electroconvulsive therapy (ECT) is one of the most effective treatment options for refractory depressed patients. To date, there are only a few predictors of response. Aim The aim was to identify predictive biomarkers of remission to ECT on a molecular level. Methods 11 patients suffering from a major depressive episode—according to the Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)—underwent 10 ECT sessions. Blood samples were taken, and the depression severity was assessed before, one hour and 24 hours after sessions 1, 4, 7, and 10 using the Montgomery Asberg Depression Rating Scale (MADRS). A MADRS total score < 12 was interpreted as remission. Results Patients remitting under ECT had significantly higher homocysteine (p < 0.001), S100B (p < 0.001), and procalcitonin (PCT) (p = 0.027) serum levels. On the contrary, serum levels of vitamin B12 (p < 0.001) and folic acid (p = 0.007) were significantly lower in remitters compared to those in nonremitters. Levels remained unchanged throughout the whole ECT course. Conclusions Our findings indicate that lower levels of vitamin B12 and folic acid associated with higher levels of homocysteine, S100B, and PCT point to a subgroup of depressed patients sensitive to ECT. Due to the limited sample size, further studies are required to replicate our findings.

show abstract

“…After completing 12 sessions of ECT, they found a decrease in the signaling of proinflammatory cytokines IL‐5 and eotaxin‐3, together with an increase in TNF‐β . Finally, several studies have shown that S100B concentrations in serum and cerebrospinal fluid are not altered after several sessions of ECT …”

mentioning

confidence: 99%

“…They did not find an additive effect of these changes with successive ECT sessions. Finally, Arts and colleagues described an increase in serum levels of the S100B protein, a marker of glial injury, 1 h and 3 h after an ECT session, but another study did not find any changes …”

mentioning

confidence: 99%

See 1 more Smart Citation

Effects of electroconvulsive therapy in the systemic inflammatory balance of patients with severe mental disorder

Bioque

MacDowell

Meseguer

et al. 2019

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Aim: There is a great interest in the role of the immune system and the inflammatory balance as key mechanisms involved in the pathophysiology of severe mental disorders. Previous studies have indicated that electroconvulsive therapy (ECT) produces changes in certain inflammatory mediators or in the immune system response. This study aimed to explore the effects of ECT on the nuclear transcription factor κB (NFκB) pathway, a main regulatory pathway of the inflammatory/immune response.Methods: Thirty subjects with a severe mental disorder receiving treatment with ECT in our center were included. Thirteen systemic biomarkers related to the NFκB pathway were analyzed right before and 2 h after a single ECT session.Results: An ECT session significantly decreased the expression of NFκB (P = 0.035) and of the inducible nitric oxide synthase (P = 0.012), and the plasma levels of nitrites (P = 0.027), prostaglandin E 2 (P = 0.049), and 15-deoxy-PGJ 2 (P < 0.001). Decrease in plasmatic levels of nitrites was greater in females than in males (P = 0.021). A positive correlation between the ECT stimulus load and changes in the expression of NFkB was found (P = 0.036). Thiobarbituric acid reactive substance levels were decreased in treatment responders and increased in non-responders (P = 0.047). Conclusion:Our study shows the effects that a single session of ECT produces on a canonical regulatory pathway of the inflammatory/innate immune system and the inflammatory balance. These biomarkers could be useful as treatment response targets and could help to clarify the biological basis of ECT action. These findings warrant greater attention in future investigations and in the translational significance of these data.

show abstract

S100 and Impact of ECT on Depression and Cognition

Abstract: The S100-beta at baseline may be a marker predicting and possibly mediating the differential impact of ECT on cognition and depression.

Cited by 30 publications

References 49 publications

Mood Disorders Are Glial Disorders: Evidence from In Vivo Studies

Mood Disorders Are Glial Disorders: Evidence from In Vivo Studies

S100B, Homocysteine, Vitamin B12, Folic Acid, and Procalcitonin Serum Levels in Remitters to Electroconvulsive Therapy: A Pilot Study

Effects of electroconvulsive therapy in the systemic inflammatory balance of patients with severe mental disorder

Contact Info

Product

Resources

About